Patrick Heron

Patrick co-leads Frazier’s Life Sciences team and invests across the spectrum of therapeutics opportunities, from early-stage drug development companies to commercial-stage pharmaceutical companies.

Patrick is a Managing Partner and co-founder of the Frazier’s Life Sciences team. He joined the firm in 1999 in Seattle and opened Frazier’s Palo Alto office in 2003. Throughout his 20 years as a General and then Managing Partner, Patrick has led or co-led investments across 30 plus companies.

Patrick has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage metabolic companies to commercial-stage dermatology and liver disease companies. Patrick has also been active in company formation around both early- and later-stage assets. He has led and served as director for many successful Frazier Life Sciences investments, including Vaxcyte (NASDAQ: PCVX), Krystal (NASDAQ: KRYS), Collegium (NASDAQ: COLL), Imago BioSciences (acquired by Merck), Ignyta (acquired by Roche), Silvergate Pharmaceuticals (acquired by CutisPharma), Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda). He currently serves on the boards of Alceptor, Alpha‑9, Arcutis Biotherapeutics (NASDAQ: ARQT), BlueWater Therapeutics, Breakwater Therapeutics, MBX Biosciences (NASDAQ: MBX), Mirum Pharmaceuticals (NASDAQ: MIRM), and Tubulis. He is also a board observer for Aspen Neuroscience and LAND.

Patrick has served on the investment committee for the Gates Foundation Strategic Investment Fund for the past 6 years.

Prior to joining Frazier Patrick helped develop McKinsey & Company’s West Coast biotechnology consulting practice, where he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate partnering, and research prioritization.

Patrick received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.